Patients Sought for New Trial of Adoptive Immunotherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 12
Volume 6
Issue 12

CHICAGO-Researchers from three midwestern centers are seeking patients with leukemia, lymphoma, or multiple myeloma who have relapsed after an allogeneic stem cell transplant for a new trial of adoptive immunotherapy.

CHICAGO—Researchers from three midwestern centers are seeking patients with leukemia, lymphoma, or multiple myeloma who have relapsed after an allogeneic stem cell transplant for a new trial of adoptive immunotherapy.

The concept of the study is that lymphocyte infusions from the original donor may induce remission. However, this approach may also be complicated by graft-versus-host disease (GVHD).

The researchers will attempt remission induction by infusion of IL-2-activated lymphocytes transduced with the herpes simplex thymidine kinase (HSTK) gene. If severe GVHD occurs, the infused lymphocytes will be killed by adminis-tration of the prodrug ganciclovir (Cytovene).

For referrals, contact Dr. Richard Burt at Northwestern University (312-908-5400), Dr. William Drobyski or Dr. William Burns at the Medical College of Wisconsin, Milwaukee (414-257-5452), or Dr. Charles Link at the Human Gene Therapy Research Institute, Des Moines, Iowa (515-241-8790).

Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
A panel of 5 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Related Content